The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Heparin-Induced Thrombocytopenia (HIT) Thrombosis Management

Recognition and treatment of immune-mediated heparin-induced thrombocytopenia with thrombosis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Heparin-Induced Thrombocytopenia (HIT) Thrombosis Management?

HIT caused by IgG antibodies against PF4-heparin complexes leading to platelet activation through Fc receptors.

Type II HIT is immune-mediated form developing 5-14 days after heparin exposure with thrombocytopenia and thrombosis risk.

Type I HIT is non-immune transient mild thrombocytopenia not associated with thrombosis or treatment changes.

HIT with thrombosis (HITT) involves arterial or venous thrombosis from prothrombotic state with substantial morbidity.

All heparin types implicated though unfractionated heparin causes higher incidence than low molecular weight heparin.

Symptoms

Thrombocytopenia developing 5-14 days after heparin initiation with platelet count drop typically more than 50% from baseline.
Arterial or venous thrombosis with limb ischemia, pulmonary embolism, deep vein thrombosis, stroke or myocardial infarction.
Skin necrosis at heparin injection sites in severe cases.
Anaphylactoid reactions to intravenous heparin in highly sensitized patients.
Adrenal hemorrhage from bilateral adrenal vein thrombosis in severe cases.

Risk Factors

Prior heparin exposure including long-term outpatient use or recent hospital admissions.
Surgical patients particularly cardiac and orthopedic surgery have higher HIT incidence.
Female sex demonstrates higher HIT risk than males.
Unfractionated heparin produces higher HIT incidence than low molecular weight heparin.
Bovine-source heparin formerly produced higher HIT than porcine source.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Significant platelet count drop during heparin therapy warrants HIT evaluation with 4Ts scoring.
  • Thrombosis development on heparin therapy with thrombocytopenia warrants urgent HIT consideration.
  • Skin necrosis at heparin injection sites or anaphylactoid reactions require immediate evaluation.
  • Suspected HIT mandates immediate heparin discontinuation pending laboratory confirmation.
  • Patients with prior HIT require lifelong heparin avoidance and alternative anticoagulation strategies.

Treatment Methods

01
Immediate discontinuation of all heparin products including catheter flushes and unfractionated heparin coatings.
02
Argatroban direct thrombin inhibitor 2 mcg/kg/min infusion adjusted to PTT 1.5-3 times baseline.
03
Bivalirudin alternative direct thrombin inhibitor particularly for renal dysfunction.
04
Fondaparinux for clinically stable HIT without overt thrombosis though off-label use.
05
Comprehensive management including imaging for thrombosis assessment, transition to oral anticoagulation with warfarin (after platelet recovery to avoid warfarin-induced skin necrosis from protein C deficiency) or direct oral anticoagulants increasingly used, lifelong heparin avoidance documentation in medical records, alternative anticoagulation strategies for future surgical and medical needs and patient education regarding HIT history and implications optimizes outcomes from this serious adverse drug reaction.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.